Physicians
Glaukos ranks #19 in the Wall Street Journal's Top 50 Venture-Funded Companies more
A Clinical Advancement
"We have brought together seasoned ophthalmic device and pharmaceutical executives who share the belief that our micro-bypass therapy will have a significant impact on alleviating the burdens of glaucoma management and aid in preserving vision."
Thomas W. Burns
President and CEO, Director
Physicians
Committed to Clinical Integrity
Since the company’s inception in January 2001, Glaukos has been committed to advancements in glaucoma management through ongoing clinical research to further develop the micro-bypass stent device. Our medical partnerships and innovative technologies are aimed at reducing the challenges and risks associated with traditional glaucoma management options, aiding in the preservation of vision, and transforming glaucoma management. The company has a robust pipeline and will be investing in multiple Phase IIIb and IV clinical trials for the iStent® micro-bypass devices.
